Evidence map›Paper›PMID 41236405›Full record

ArticleCancer2025

Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly.

Chi Young Ok, Anuya Natu, Parnaz Daneshpajouhnejad, Lamiaa A Fathalla, Emily Symes, Paul Barone, Anna Shestakova, Kathryn K Foucar, Carlos Bueso-Ramos, Guillermo Montalban-Bravo and 8 more

Erratum issuedAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Chi Young OkDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-6822-7880
Anuya NatuDepartment of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Parnaz DaneshpajouhnejadDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Lamiaa A FathallaDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Emily SymesDepartment of Pathology, University of Chicago, Chicago, Illinois, USA.
Paul BaroneDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.
Anna ShestakovaDepartment of Pathology, Associated Regional and University Pathologist (ARUP) Laboratories, University of Utah, Salt Lake City, Utah, USA.
Kathryn K FoucarDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
Carlos Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-4533-5176
Attilio OraziDepartment of Pathology, Texas Tech Health Sciences Center, El Paso, Texas, USA.
Mrinal PatnaikDepartment of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Robert HasserjianDepartment of Pathology, Massachusetts General Hospital, Massachusetts, Massachusetts, USA.
Daniel ArberDepartment of Pathology, University of Chicago, Chicago, Illinois, USA.
Julia T GeyerDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.
Adam BaggDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kaaren K ReichardDepartment of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Sa A WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic myelomonocytic leukemia (CMML) is largely a disease of individuals older than 50 years; its occurrence in patients aged 50 years and younger is rare. The authors sought to characterize the clinicopathologic features and genetic profile of young-onset (age 50 years and younger) CMML (y-CMML) compared with older onset (older than 50 years) CMML (o-CMML).

methodsThe authors conducted a multi-institutional study of 32 patients with y-CMML and 119 patients with o-CMML, analyzing clinical, morphologic, cytogenetic, and molecular data.

resultsPatients who had y-CMML frequently presented with splenomegaly (59% vs. 11%; p < .001) and hepatomegaly (25% vs. 2%; p < .001) compared with those who had o-CMML. Although the overall incidence of cytogenetic abnormalities was similar, patients who had y-CMML exhibited distinct mutational patterns. PTPN11 mutations were significantly more common in y-CMML (13% vs. 3%; p = .034) than in o-CMML, whereas TET2 (6% vs. 57%; p < .001) and SRSF2 (16% vs. 46%; p = .002) mutations were significantly less frequent. In addition, multi-hit TET2 (6% vs. 34%; p = .002) and TET2-SRSF2 (3% vs. 29%; p = .003) co-mutations were rare in y-CMML. However, the molecular differences did not affect the CMML-specific risk-stratification categories because the clinical outcomes, including overall survival and leukemia-free survival, did not differ between the two groups.

conclusionsCMML in patients aged 50 years and younger is rare and presents with unique clinical and mutational features, suggesting a distinct pathogenesis.

Indexed as

Leukemia, Myelomonocytic, ChronicAdultAgedAged, 80 and overAge FactorsAge of OnsetDioxygenasesDNA-Binding ProteinsFemaleHumansMaleMiddle AgedMutationProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene ProteinsSerine-Arginine Splicing FactorsDioxygenasesDNA-Binding ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene ProteinsPTPN11 protein, humanSerine-Arginine Splicing FactorsSRSF2 protein, humanTET2 protein, humanchronic myelomonocytic leukemia (CMML)multi‐hit TET2SRSF2‐TET2 co‐mutationyoung

Identifiers

PMID41236405
PMCPMC12617386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.